Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma
Autor: | Tanja Podkonjak, Holly Cranmer, Julia Scarisbrick, Grant McCarthy, Cameron Lilley, Lung-I Cheng |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Journal of Comparative Effectiveness Research. 11:193-202 |
ISSN: | 2042-6313 2042-6305 |
Popis: | Aim: To assess the cost–effectiveness of brentuximab vedotin (BV) versus physician’s choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. Materials & methods: A partitioned-survival model was developed from the National Health Service perspective in England and Wales. Model inputs were informed by the ALCANZA trial, real-world UK data, published literature or clinical experts. Results: Over the modeled lifetime, BV dominated physician’s choice and provided an additional 1.58 life-years and 1.09 higher quality-adjusted life years with a net cost saving of £119,565. The net monetary benefit was £152,326 using a willingness-to-pay threshold of £30,000/quality-adjusted life year. Results were robust in sensitivity and scenario analyses. Conclusion: BV is a highly cost-effective treatment for advanced cutaneous T-cell lymphoma. |
Databáze: | OpenAIRE |
Externí odkaz: |